surmount-4 tirzepatide withdrawal weight regain Time to plateau with treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity Tirzepatide for maintenance of bodyweight

Adults with a BMI of 30 kg/m or higher-or at least 27 kg/m with weight-related comorbidities-who have not succeeded with lifestyle changes alone and who do not have contraindications such as heart disease, uncontrolled hypertension, glaucoma, hyperthyroidism, pregnancy, or a history of drug abuse

Consult with your physician or specialist if you want to take a more holistic approach

Treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to severe liver fibrosis

This offers a mechanistically different perspective for your research compared to the direct sleep-inducing properties often associated with DSIP